RXi Pharmaceuticals Corp Share Price Nasdaq
Equities
US74979C3034
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
21/05 | Phio Pharmaceuticals Files $100 Million Mixed Shelf | MT |
15/05 | Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study | MT |
Sales 2024 * | - | Sales 2025 * | 75M 6.26B | Capitalization | 3.45M 288M |
---|---|---|---|---|---|
Net income 2024 * | -9M -751M | Net income 2025 * | 47M 3.92B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.05 x |
P/E ratio 2024 * |
-0.41
x | P/E ratio 2025 * |
0.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/17/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Director/Board Member | 73 | 02/22/02 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/13/18 |
1st Jan change | Capi. | |
---|---|---|
+50.82% | 58.06B | |
-5.84% | 40.53B | |
+37.66% | 38.99B | |
+13.05% | 26.7B | |
-12.01% | 26.56B | |
-21.68% | 18.98B | |
+1.21% | 12.17B | |
+23.03% | 12B | |
+26.23% | 11.92B |